{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:21:16Z","timestamp":1791555676644,"version":"4.3.4"},"reference-count":85,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003093","name":"Ministry of Higher Education, Malaysia","doi-asserted-by":"publisher","award":["FRGS\/1\/2019\/SKK06\/UKM\/02\/7"],"award-info":[{"award-number":["FRGS\/1\/2019\/SKK06\/UKM\/02\/7"]}],"id":[{"id":"10.13039\/501100003093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has a high affinity towards pro-survival BCL-2 family proteins (i.e., BCL-XL, BCL-2, BCL-W) to induce cell apoptosis effectively. A single navitoclax action potently ameliorates several tumor progressions, including blood and bone marrow cancer, as well as small cell lung carcinoma. Not only that, but navitoclax alone also therapeutically affects fibrotic disease. Nevertheless, outcomes from the clinical trial of a single navitoclax agent in patients with advanced and relapsed small cell lung cancer demonstrated a limited anti-cancer activity. This brings accumulating evidence of navitoclax to be used concomitantly with other chemotherapeutic agents in several solid and non-solid tumors that are therapeutically benefiting from navitoclax treatment in preclinical studies. Initially, we justify the anti-cancer role of navitoclax in combination therapy. Then, we evaluate the current evidence of navitoclax in combination with the chemotherapeutic agents comprehensively to indicate the primary regulator of this combination strategy in order to produce a therapeutic effect.<\/jats:p>","DOI":"10.3390\/pharmaceutics13091353","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T04:07:28Z","timestamp":1630382848000},"page":"1353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence"],"prefix":"10.3390","volume":"13","author":[{"given":"Nur Syahidah","family":"Nor Hisam","sequence":"first","affiliation":[{"name":"Programme of Biomedical Science, Centre for Toxicology & Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizah","family":"Ugusman","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-0605","authenticated-orcid":false,"given":"Nor Fadilah","family":"Rajab","sequence":"additional","affiliation":[{"name":"Center for Healthy Ageing & Wellness, Programme of Biomedical Science, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2735-3274","authenticated-orcid":false,"given":"Mohd Faizal","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fenech","sequence":"additional","affiliation":[{"name":"Center for Healthy Ageing & Wellness, Programme of Biomedical Science, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia"},{"name":"Genome Health Foundation, North Brighton, SA 5048, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Ling","family":"Liew","sequence":"additional","affiliation":[{"name":"Programme of Biomedical Science, Centre for Toxicology & Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-8316","authenticated-orcid":false,"given":"Nur Najmi","family":"Mohamad Anuar","sequence":"additional","affiliation":[{"name":"Programme of Biomedical Science, Centre for Toxicology & Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_3","first-page":"1016","article-title":"Revisiting the hallmarks of cancer","volume":"7","author":"Fouad","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gde.2010.12.001","article-title":"Apoptosis and oncogenesis: Give and take in the BCL-2 family","volume":"21","author":"Llambi","year":"2011","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrc3773","article-title":"Inside and out: The activities of senescence in cancer","volume":"14","author":"Young","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Labi, V., and Erlacher, M. (2015). How cell death shapes cancer. Cell Death Dis., 6.","DOI":"10.1038\/cddis.2015.20"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Razak, N.A., Abu, N., Ho, W.Y., Zamberi, N.R., Tan, S.W., Alitheen, N.B., Long, K., and Yeap, S.K. (2019). Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Sci. Rep., 9.","DOI":"10.1038\/s41598-018-37796-w"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/carcin\/bgr076","article-title":"Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases","volume":"32","author":"Zhao","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: Molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"DeBeradinis, R.J., and Chandel, N.S. (2016). Fundamentals of cancer metabolism. Sci. Adv., 2.","DOI":"10.1126\/sciadv.1600200"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12672-018-0342-9","article-title":"RAGE and its ligands: Molecular interplay between glycation, inflammation, and halmarks of cancer\u2014A Review","volume":"9","author":"Palanissami","year":"2018","journal-title":"Horm. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1535-6108(02)00241-6","article-title":"Apoptosis-targeted therapies for cancer","volume":"3","author":"Reed","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_15","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson","year":"2000","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"D\u2019Aguanno, S., and Del Bufalo, D. (2020). Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: Current overview in cancer. Cells, 9.","DOI":"10.3390\/cells9051287"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Campbell, K.J., and Tait, S.W.G. (2018). Targeting BCL-2 regulated apoptosis in cancer. Open Biol., 8.","DOI":"10.1098\/rsob.180002"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jnutbio.2015.12.019","article-title":"Gamma-tocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells","volume":"31","author":"Tan","year":"2016","journal-title":"J. Nutr. Biochem."},{"key":"ref_19","first-page":"224","article-title":"Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-hodgkin lymphoma","volume":"12","author":"Ng","year":"2014","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_20","unstructured":"(2021, May 28). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=bcl-2+inhibitor%2C+cancer&cntry=&state=&city=&dist=&Search=Search."},{"key":"ref_21","first-page":"53","article-title":"Venclexta (Venetoclax) first BCL-2 inhibitor approved for high-risk relapsed chronic lymphocytic leukemia","volume":"7","author":"Raedler","year":"2017","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2017.188","article-title":"Bcl-2 on the brink of breakthroughs in cancer treatment","volume":"25","author":"Reed","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of Navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Mohamad Anuar, N.N., Nor Hisam, N.S., Liew, S.L., and Ugusman, A. (2020). Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic agent. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.564108"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1158\/1535-7163.MCT-09-0651","article-title":"Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia\/lymphoma cell Lines","volume":"9","author":"Tahir","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00280-009-1232-1","article-title":"The Bcl-2 Inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors In Vivo","volume":"66","author":"Ackler","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Falzone, L., Salomone, S., and Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01300"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/0008-5472.CAN-16-0470","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"76","author":"DeVita","year":"2016","journal-title":"Cancer Res."},{"key":"ref_31","first-page":"1258","article-title":"Intensive combination chemotherapy and X-irradiation in Hodgkin\u2019s disease","volume":"27","author":"Moxley","year":"1967","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-73-6-881","article-title":"Combination chemotherapy in the treatment of advanced Hodgkin\u2019s disease","volume":"73","author":"Devita","year":"1970","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2147\/DDDT.S67592","article-title":"Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: Multi-institutional retrospective analysis","volume":"8","author":"Peng","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.11-4-325","article-title":"Capecitabine monotherapy: Safe and effective treatment for metastatic breast cancer","volume":"11","author":"Ershler","year":"2006","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.4-1-17","article-title":"Monotherapy of metastatic breast cancer: A review of newer agents","volume":"4","author":"Vogel","year":"1999","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Suvarna, V., Singh, V., and Murahari, M. (2019). Current Overview on the Clinical Update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur. J. Pharmacol., 862.","DOI":"10.1016\/j.ejphar.2019.172655"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.21335","article-title":"The British childhood cancer survivor study: Objectives, methods, population structure, response rates and initial descriptive information","volume":"50","author":"Stevens","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1089\/thy.2013.0057","article-title":"Clinical responses to Vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation","volume":"23","author":"Kim","year":"2013","journal-title":"Thyroid"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Johnson, D.B., Estrada, M.V., Salgado, R., Sanchez, V., Doxie, D.B., Opalenik, S.R., Vilgelm, A.E., Feld, E., Johnson, A.S., and Greenplate, A.R. (2016). Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy. Nat. Commun., 7.","DOI":"10.1038\/ncomms10582"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shen, Q., Li, J., Mai, J., Zhang, Z., Fisher, A., Wu, X., Li, Z., Ramirez, M.R., Chen, S., and Shen, H. (2018). Sensitizing non-small cell lung cancer to BCL-XL-targeted apoptosis. Cell Death Dis., 9.","DOI":"10.1038\/s41419-018-1040-9"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2011.90","article-title":"Novel strategies for the treatment of small-cell lung carcinoma","volume":"8","author":"William","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Homayouni","year":"2017","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/ijo.2018.4661","article-title":"From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (review)","volume":"54","author":"Schirrmacher","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1570163812666150602144310","article-title":"Targeted cancer therapy: The next generation of cancer treatment","volume":"12","author":"Baudino","year":"2015","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/15384047.2015.1108485","article-title":"Combination with Vorinostat overcomes ABT-263 (Navitoclax) resistance of small cell lung cancer","volume":"17","author":"Nakajima","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: Challenges and opportunities in drug discovery department of life science informatics, B-IT, LIMES program unit chemical biology and medicinal","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cib.21554","article-title":"Anti-cancer drug discovery and development Bcl-2 family small molecule inhibitors","volume":"5","author":"Liu","year":"2012","journal-title":"Commun. Integr. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/SCS.0000000000002792","article-title":"The clinical features and expression of bcl-2, Cyclin D1, p53, and proliferating cell nuclear antigen in syndromic and nonsyndromic keratocystic odontogenic tumor","volume":"27","author":"Ibrahim","year":"2016","journal-title":"J. Craniofac. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1593\/neo.05691","article-title":"(-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma In Vivo","volume":"8","author":"Wolter","year":"2006","journal-title":"Neoplasia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.29245\/2578-2967\/2019\/4.1172","article-title":"Rational strategies for combining Bcl-2 inhibition with targeted drugs for anti-tumor synergy","volume":"3","author":"Schwab","year":"2019","journal-title":"J. Cancer Treat. Diagn."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-07-4622","article-title":"Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models","volume":"14","author":"Shoemaker","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1158\/0008-5472.CAN-10-4336","article-title":"Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-XL","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.tiv.2017.09.023","article-title":"Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin","volume":"46","author":"Lee","year":"2018","journal-title":"Toxicol. Vitr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s13402-019-00431-5","article-title":"ABT-263 exhibits apoptosis-inducing potential in oral cancer cells by targeting C\/EBP-homologous protein","volume":"42","author":"Yang","year":"2019","journal-title":"Cell. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent Navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Mukherjee, N., Skees, J., Todd, K.J., West, D.A., Lambert, K.A., Robinson, W.A., Amato, C.M., Couts, K.L., Van Gulick, R., and Macbeth, M. (2020). MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis., 11.","DOI":"10.1038\/s41419-020-2646-2"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2011.38.5591","article-title":"PAX3\/FOXO1 fusion gene status is the key prognostic molecular marker in Rhabdomyosarcoma and significantly improves current risk stratification","volume":"30","author":"Missiaglia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/0008-5472.CAN-19-1479","article-title":"Aurora A kinase inhibition destabilizes PAX3-FOXO1 and MYCN and synergizes with Navitoclax to induce Rhabdomyosarcoma cell death","volume":"80","author":"Ommer","year":"2020","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ng.3602","article-title":"The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis","volume":"48","author":"Gibson","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1586\/14737140.2016.1168699","article-title":"The clinical management of inoperable endometrial carcinoma","volume":"16","author":"Palisoul","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_63","first-page":"1237","article-title":"Cisplatin cytotoxicity is increased by Mifepristone in cervical carcinoma: An In Vitro and In Vivo study","volume":"22","author":"Jurado","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1039\/D0BM00112K","article-title":"Ultra PH-sensitive polymeric nanovesicles co-deliver Doxorubicin and Navitoclax for synergetic therapy of endometrial carcinoma","volume":"8","author":"Ding","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1530\/EC-19-0045","article-title":"Clinical significance of the BRAF V600E mutation in PTC and its effect on radioiodine therapy","volume":"8","author":"Zhu","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of Vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomized, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1210\/jc.2014-2246","article-title":"Efficacy and tolerability of Vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer: M.D. Anderson cancer center off label experience","volume":"100","author":"Dadu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1089\/thy.2018.0511","article-title":"Combination treatment with the BRAF V600E inhibitor Vemurafenib and the BH3 mimetic Navitoclax for BRAF-mutant thyroid carcinoma","volume":"29","author":"Jeong","year":"2019","journal-title":"Thyroid"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1535-7163.MCT-12-0767","article-title":"A novel small-molecule inhibitor of Mcl-1 blocks pancreatic cancer growth In Vitro and In Vivo","volume":"13","author":"Abulwerdi","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.bbamcr.2013.08.006","article-title":"Simultaneous knock-down of Bcl-XL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells","volume":"1833","author":"Takahashi","year":"2013","journal-title":"Biochim. Biophys. Acta BBA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1158\/0008-5472.CAN-11-4106","article-title":"Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B-cells","volume":"72","author":"Mazumder","year":"2012","journal-title":"Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.2174\/0929867324666170912092659","article-title":"Recent advances in cancer drug development: Targeting induced myeloid cell leukemia-1 (Mcl-1) differentiation protein","volume":"24","author":"Abid","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molcel.2010.11.035","article-title":"The pro-apoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose","volume":"40","author":"Lowman","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/mol.119.116855","article-title":"CDK5 inhibitor downregulates Mcl-1 and sensitizes pancreatic cancer cell lines to Navitoclax","volume":"96","author":"Kour","year":"2019","journal-title":"Mol. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.13005\/bpj\/1617","article-title":"Lung cancers and the roles of natural compounds as potential chemotherapeutic and chemopreventive agents","volume":"12","author":"Surien","year":"2019","journal-title":"Biomed. Pharmacol. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/sj.leu.2404760","article-title":"Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa","volume":"21","author":"Inoue","year":"2007","journal-title":"Leukemia"},{"key":"ref_79","first-page":"3645","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3324\/haematol.2013.100917","article-title":"Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction","volume":"99","author":"Thanasopoulou","year":"2014","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/gcc.22100","article-title":"NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR","volume":"52","author":"Akiki","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_82","first-page":"2400","article-title":"NUP98\/NSD1 and FLT3\/ITD coexpression is more prevalent in younger aml patients and leads to induction failure: A COG and SWOG report","volume":"124","author":"Ostronoff","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41375-018-0327-2","article-title":"Dasatinib and Navitoclax act synergistically to target NUP98-NSD1+\/FLT3-ITD+ acute myeloid leukemia","volume":"33","author":"Kivioja","year":"2019","journal-title":"Leukemia"},{"key":"ref_84","first-page":"1587","article-title":"Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia","volume":"122","author":"Koss","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7558","DOI":"10.1158\/1078-0432.CCR-17-1231","article-title":"Modulation of Navitoclax sensitivity by Dihydroartemisinin-mediated MCL-1 repression in BCR-ABL+ B-lineage acute lymphoblastic leukemia","volume":"23","author":"Budhraja","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:20Z","timestamp":1760165660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/9\/1353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":85,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["pharmaceutics13091353"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13091353","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]}}}